Altimmune, Inc. (NASDAQ:ALT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT) have earned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $20.00.

A number of research analysts recently commented on ALT shares. Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Altimmune in a research report on Thursday. B. Riley reissued a “buy” rating and set a $20.00 price target on shares of Altimmune in a report on Monday, August 12th. Finally, UBS Group began coverage on Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ALT. Larson Financial Group LLC purchased a new position in shares of Altimmune during the 3rd quarter worth $31,000. CANADA LIFE ASSURANCE Co acquired a new stake in Altimmune in the 1st quarter worth about $44,000. TFO Wealth Partners LLC purchased a new stake in Altimmune in the 1st quarter valued at about $51,000. Horizon Wealth Management LLC acquired a new position in shares of Altimmune during the 2nd quarter valued at about $66,000. Finally, PFG Investments LLC purchased a new position in shares of Altimmune during the 2nd quarter worth about $67,000. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

Altimmune Trading Down 9.9 %

Shares of NASDAQ:ALT opened at $7.61 on Monday. The company has a market capitalization of $541.22 million, a price-to-earnings ratio of -4.91 and a beta of 0.09. Altimmune has a 12-month low of $2.34 and a 12-month high of $14.84. The business has a 50-day moving average price of $7.02 and a 200 day moving average price of $6.91.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.03. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The company had revenue of $0.01 million for the quarter. During the same quarter last year, the company earned ($0.39) EPS. As a group, equities research analysts predict that Altimmune will post -1.36 earnings per share for the current fiscal year.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.